Injection burden and treatment intervals of aflibercept in observe‐and‐plan regimen for neovascular age‐related macular degeneration
Acta Ophthalmologica · 2024
DOI: 10.1111/aos.16709 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Ophthalmologica, 2024. Verfasst von Yousif Subhi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Receptors, Vascular Endothelial Growth Factor, Intravitreal Injections, Wet Macular Degeneration. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Purpose
The Observe‐and‐Plan (O&P) regimen allows for individualised treatment. In this study, we evaluated injection burden and intervals using aflibercept in an O&P regimen for eyes with neovascular age‐related macular degeneration (AMD).
Methods
This was a retrospective registry‐based study of treatment‐naïve eyes with neovascular AMD. Treatment data were compiled for 3 years after commencement of intravitreal aflibercept therapy. We evaluated clinical consequences at the first follow‐up after loading dose, the proportion of patients who obtained and kept dry macula after loading dose, number of injections and intervals between injections.
Results
Data were obtained for 1103 eyes. After loading dose, 0.4% were lost to follow‐up, 7.5% discontinued, 50.9% booked for further injections and 41.3% booked for monthly observations. After loading dose, the macula remained dry in 49.2% at 3 months, 34.0% at 6 months, 23.7% at 12 months and 15.2% at 24 months. For the entire population, median cumulative total number of injections was 7, 12 and 15, after 1, 2 and 3 years, respectively. After the 3rd year, the proportion of eyes in the short 4–6 weeks treatment interval was 51.1%, 8 weeks interval was kept in 14.4% and the extended treatment intervals of 10 and 12 weeks was possible in 34.4%.
Conclusion
After loading dose, one in two eyes required further injections. A large proportion required therapy with shorter intervals than the label‐recommended 8 weeks. The large majority of those who obtained a dry macula after loading dose turned exudative again, mostly within the first 3 months.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark.
- Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark.
- Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
- Department of Ophthalmology, Semmelweis University, Budapest, Hungary.
- Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Yousif Subhi, Miklos Schneider
Zitieren
APA
Subhi, Y., Schneider, M., Hajari, J. N., & la Cour, M. (2024). Injection burden and treatment intervals of aflibercept in observe‐and‐plan regimen for neovascular age‐related macular degeneration. Acta Ophthalmologica. https://doi.org/10.1111/aos.16709
Vancouver
Subhi Y, Schneider M, Hajari JN, la Cour M. Injection burden and treatment intervals of aflibercept in observe‐and‐plan regimen for neovascular age‐related macular degeneration. Acta Ophthalmologica. 2024. doi:10.1111/aos.16709
BibTeX
@article{Subhi2024,
author = {Subhi, Yousif and Schneider, Miklos and Hajari, Javad Nouri and la Cour, Morten},
title = {Injection burden and treatment intervals of aflibercept in observe‐and‐plan regimen for neovascular age‐related macular degeneration},
journal = {Acta Ophthalmologica},
year = {2024},
doi = {10.1111/aos.16709}
}
EUVIMED